These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Androgen Deprivation Therapy-Linked Cardiovascular Disease Risk: Still Unresolved. Azvolinsky A J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26341000 [No Abstract] [Full Text] [Related]
4. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Conteduca V; Di Lorenzo G; Tartarone A; Aieta M Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk during androgen deprivation therapy for prostate cancer. Jones TH BMJ; 2011 May; 342():d3105. PubMed ID: 21610041 [No Abstract] [Full Text] [Related]
8. Researchers probe consequences of androgen deprivation for prostate cancer. Friedrich MJ JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787 [No Abstract] [Full Text] [Related]
9. [Cardiovascular risks of androgen deprivation therapy for prostate cancer]. Miller K Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571 [TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. Basaria S J Androl; 2008; 29(5):534-9. PubMed ID: 18567642 [TBL] [Abstract][Full Text] [Related]
11. I'm on androgen deprivation therapy (ADT) for prostate cancer. I've heard that it may cause heart problems. Should I be worried? Johns Hopkins Med Lett Health After 50; 2010 May; 22(3):8. PubMed ID: 20518140 [No Abstract] [Full Text] [Related]
12. Risk of fracture after androgen deprivation for prostate cancer. Walsh PC J Urol; 2005 Sep; 174(3):929-30. PubMed ID: 16093991 [No Abstract] [Full Text] [Related]
13. Does the benefit justify the risk? Albertsen PC J Natl Cancer Inst; 2010 Jan; 102(1):4-5. PubMed ID: 19996059 [No Abstract] [Full Text] [Related]
14. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Greiman AK; Keane TE Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429 [TBL] [Abstract][Full Text] [Related]
15. Weighing up the risks and benefits of androgen deprivation therapy. Rees J Practitioner; 2014 May; 258(1771):5. PubMed ID: 25055405 [No Abstract] [Full Text] [Related]
16. Androgen deprivation therapy and cardiovascular complications. Poljak Z; Hulin I; Maruscakova L; Carter A; Mladosievicova B Bratisl Lek Listy; 2016; 117(10):557-561. PubMed ID: 28621142 [TBL] [Abstract][Full Text] [Related]
17. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. Wadhwa VK; Weston R; Mistry R; Parr NJ BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564 [TBL] [Abstract][Full Text] [Related]
18. Abiraterone and MVD3100 take androgen deprivation to a new level. Schmidt C J Natl Cancer Inst; 2011 Feb; 103(3):175-6. PubMed ID: 21242338 [No Abstract] [Full Text] [Related]